The U.S. government on Tuesday named the 15 new drugs targeted for Medicare price negotiations for 2028, including Gilead ...

The striking benefits achieved with emerging treatment options for recalcitrant connective tissue diseases offer the ...

Boehringer Ingelheim has added another drug to its immunology pipeline, licensing an inflammatory bowel disease (IBD) ...

AI and genetics are creating a 'seismic shift' in the pharmaceutical business, experts on Asian Financial Forum panel say ...

Boehringer Ingelheim has penned a 1.05 billion euro ($1.26 billion) biobucks deal for Simcere’s preclinical inflammatory bowel disease (IBD) bispecific antibody. | Boehringer Ingelheim has penned a 1.

The AHA Jan. 26 urged the Health Resources and Services Administration to take immediate action to stop a new Eli Lilly and ...

The American Hospital Association is asking the Trump administration to stop Eli Lilly from enacting a new policy as part of ...

The ongoing surge in licensing deals for early drug prospects should continue this year and involve more cell and gene ...

The American Hospital Association (AHA) expresses serious concerns with the recent announcement by Eli Lilly and Company (Lilly) to require 340B covered entities to submit claims data for all ...

What do you get when you insert a molecular glue degrader into an antibody-drug conjugate (ADC)? Fortitude Biomedicines is in ...

One llama is sprawled on the grass with its neck craned, basking in a patch of sunshine. Another stands on a dirt hill, ears ...

The market is poised for growth (12.88% CAGR), driven by high demand for equipment due to capacity expansions, and the adoption of single-use systems, continuous bioprocessing, and digital twinsDublin ...